By Devika Patel
Knoxville, Tenn., July 10 - Threshold Pharmaceuticals, Inc. said it plans to conduct an $18.3 million private placement of stock.
The company will sell 53,823,530 common shares at $0.34 apiece.
Investors also will receive warrants for 21,529,413 common shares. Each warrant is exercisable at $0.39 for five years.
Lazard Freres & Co. LLC and MTS Securities, LLC are the placement agents.
Proceeds will be used to complete the company's ongoing phase 1/2 clinical trial evaluating TH-302, its Hypoxia-Activated Prodrug for the treatment of various solid tumors, to complete at least one additional phase 1/2 clinical trial in a new indication and to initiate at least one controlled phase 2 clinical trial of TH-302 alone or in combination with chemotherapy, on preclinical activities related to another HAP clinical candidate and for general corporate purposes, including working capital.
Threshold is a biotechnology company based in Redwood City, Calif., that develops small molecule therapeutics for the potential treatment of cancer.
| Issuer: | Threshold Pharmaceuticals, Inc.
|
| Issue: | Common shares
|
| Amount: | $18.3 million
|
| Shares: | 53,823,530
|
| Price: | $0.34
|
| Warrants: | 50% coverage
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $0.39
|
| Agents: | Lazard Freres & Co. LLC and MTS Securities, LLC
|
| Pricing date: | July 10
|
| Stock symbol: | Nasdaq: THLD
|
| Stock price: | $0.3101 at close July 10
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
